Jason Patrick Meyenburg - 03 Jan 2022 Form 4 Insider Report for Gemini Therapeutics, Inc. /DE (IRON)

Reporting relationship
Chief Executive Officer, Director
Issuer ticker
IRON
Reported as of
03 Jan 2022
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
05 Jan 2022, 15:08:07 UTC
Prior SEC filing
18 May 2021
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Brian Piekos, attorney-in-fact

Key filing fact

Jason Patrick Meyenburg filed Form 4 for Gemini Therapeutics, Inc. /DE (IRON) on 05 Jan 2022.

Key facts

  • This page summarizes Jason Patrick Meyenburg's Form 4 filing for Gemini Therapeutics, Inc. /DE (IRON).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 05 Jan 2022, 15:08.

Change

  • Previous filing in this sequence was filed on 18 May 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRON transaction Derivative

Restricted Stock Units

Award

Transaction value
$0
Shares
+123,600
Change %
Price
$0.000000
Shares after
123,600
Date
03 Jan 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
123,600
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock.

Footnote F2

These Restricted Stock Units shall vest in accordance with certain performance based metrics.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .